Andere talen Poseida Therapeutics, Inc.

Aandelen

PSTX

US73730P1084

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,77 ^USD	+14,46%		+33,82%	-17,56%

08/04	Poseida Therapeutics, Inc. Presenteert nieuwe Fase 1-gegevens op AACR 2024 ter ondersteuning van het potentieel van P-BCMA-Allo1 allogene CAR-T-therapie voor een breed scala aan patiënten met multipel myeloom	CI
25/03	Poseida Therapeutics, Inc. benoemt Syed Rizvi tot Chief Medical Officer met ingang van 1 april 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	03:31
Malin Corp investee signs agreement with Astellas Pharma	01/05
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	01/05
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	01/05
Poseida Therapeutics, Inc. and Xyphos Biosciences, Inc. Enter into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology	01/05
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting	19/04
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus	17/04
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma	08/04
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	01/04
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer	25/03
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024	25/03
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	19/03
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M	07/03
Poseida Therapeutics : Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 - Form 8-K	07/03
Poseida Therapeutics, Inc. Announces Executive Changes	07/03
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	04/03
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Biotechnology Index	15/12
Poseida Therapeutics Reports Positive Results of Phase 1 Blood Cancer Treatment Trial	11/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Poseida Therapeutics, Inc.

Aandelen

PSTX

US73730P1084

Andere talen

Filters